dc.creator | Vázquez-Bourgon, Javier | es |
dc.creator | Ortiz García de la Foz, Víctor | es |
dc.creator | Gómez-Revuelta, Marcos | es |
dc.creator | Mayoral-van Son, Jaqueline | es |
dc.creator | Juncal-Ruiz, María | es |
dc.creator | Garrido-Torres, Nathalia | es |
dc.creator | Crespo Facorro, Benedicto | es |
dc.date.accessioned | 2023-06-12T14:31:32Z | |
dc.date.available | 2023-06-12T14:31:32Z | |
dc.date.issued | 2022-05-31 | |
dc.identifier.citation | Vázquez-Bourgon, J., Ortiz García de la Foz, V., Gómez-Revuelta, M., Mayoral-van Son, J., Juncal-Ruiz, M., Garrido-Torres, N. y Crespo Facorro, B. (2022). Aripiprazole and Risperidone Present Comparable Long-Term Metabolic Profiles: Data From a Pragmatic Randomized Controlled Trial in Drug-Naïve First-Episode Psychosis. International Journal of Neuropsychopharmacology (IJNP), 25 (10), 795-806. https://doi.org/10.1093/ijnp/pyac033. | |
dc.identifier.issn | 1461-1457; 1469-5111 | es |
dc.identifier.uri | https://hdl.handle.net/11441/147093 | |
dc.description.abstract | Objective
Aripiprazole and risperidone are 2 of the most used second-generation antipsychotics (SGAs) worldwide. Previous evidence shows a similar effect of these SGAs on weight and metabolic changes in the short term. However, a longer period is necessary for a better assessment of the SGA´s metabolic profile. We aimed to compare the long-term (1-year) metabolic profile of these 2 antipsychotics on a sample of drug-naïve first episode-psychosis (FEP) patients.
Methods
A total 188 drug-naïve patients, suffering from a first episode of non-affective psychosis (FEP), were randomly assigned to treatment with either aripiprazole or risperidone. Weight and glycemic/lipid parameters were recorded at baseline and after 1-year follow-up.
Results
We observed significant weight increments in both groups (9.2 kg for aripiprazole and 10.5 kg for risperidone) after 1 year of treatment. Despite this, weight and body mass index changes did not significantly differ between treatment groups (P > .05). Similarly, both treatment groups presented similar metabolic clinical impact with a comparable increase in the proportion of participants meeting criteria for metabolic disorders such as obesity or hypercholesterolemia, but not for metabolic syndrome (Δ9.2% vs Δ4.3%) or hypertriglyceridemia (Δ21.9% vs Δ8.0%), where aripiprazole showed worse outcomes than risperidone.
Conclusion
This study shows that aripiprazole and risperidone share a similar long-term metabolic profile. After 1 year of antipsychotic treatment, drug-naïve FEP patients in both treatment groups presented a significant increase in weight and metabolic changes, leading to a greater prevalence of metabolic disorders. | es |
dc.format | application/pdf | es |
dc.format.extent | 12 p. | es |
dc.language.iso | eng | es |
dc.publisher | Oxford University Press | es |
dc.relation.ispartof | International Journal of Neuropsychopharmacology (IJNP), 25 (10), 795-806. | |
dc.rights | Atribución-NoComercial 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | * |
dc.subject | Metabolism | es |
dc.subject | weight gain | es |
dc.subject | treatment-naïve | es |
dc.subject | second-generation antipsychotic | es |
dc.subject | schizophrenia | es |
dc.title | Aripiprazole and Risperidone Present Comparable Long-Term Metabolic Profiles: Data From a Pragmatic Randomized Controlled Trial in Drug-Naïve First-Episode Psychosis | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Psiquiatría | es |
dc.relation.projectID | INT/A20/04 | es |
dc.relation.projectID | INT/A21/10 | es |
dc.relation.projectID | PI020499 | es |
dc.relation.projectID | PI050427 | es |
dc.relation.projectID | PI060507 | es |
dc.relation.publisherversion | https://academic.oup.com/ijnp/article/25/10/795/6596170 | es |
dc.identifier.doi | 10.1093/ijnp/pyac033 | es |
dc.journaltitle | International Journal of Neuropsychopharmacology (IJNP) | es |
dc.publication.volumen | 25 | es |
dc.publication.issue | 10 | es |
dc.publication.initialPage | 795 | es |
dc.publication.endPage | 806 | es |
dc.contributor.funder | AstraZeneca | es |
dc.contributor.funder | Bristol-Myers Squibb | es |
dc.contributor.funder | Instituto de Investigacion Sanitaria Valdecilla | es |
dc.contributor.funder | Instituto de Salud Carlos III | es |
dc.contributor.funder | Janssen Johnson Johnson | es |
dc.contributor.funder | Lundbeck | es |
dc.contributor.funder | Pfizer | es |